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Abstract
Schizophrenia is a severe psychiatric disorder which influences around 1 % of the worldwide population. Differences
between male and female patients with schizophrenia have been noted. There is an earlier age of onset in males
compared with females with this diagnosis, and in addition, there are differences in symptom profiles between the
sexes. The underlying molecular mechanism of sex difference remains unclear. Here we present a comprehensive
analysis to reveal the sex differences in gene expression in schizophrenia with stringent statistics criteria. We compiled a
data set consisting of 89 male controls, 90 male schizophrenia patients, 35 female controls and 32 female schizophrenia
patients from six independent studies of the prefrontal cortex (PFC) in postmortem brain. When we tested for a sex by
diagnosis interaction on gene expression, 23 genes were up-regulated and 23 genes were down-regulated in the male
group (q-value < 0.05), several genes are related to energy metabolism, while 4 genes are located on sex chromosome.
No genes were statistically significant in the female group when multiple testing correction were conducted
(q-value <0.05), most likely due to the small sample size. Our protocol and results from the male group provide a
starting point for identifying the underlying different mechanism between male and female schizophrenia patients.
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Introduction
Schizophrenia is a severe psychiatric disorder with a
population frequency of approximately 1 % [30].
Schizophrenia is a syndrome characterized by positive
symptoms such as delusions, hallucinations, disorganized
speech and grossly disorganized or catatonic behavior;
negative symptoms such as affective flatterning, alogia, or
avolition [26, 30]. The etiology and pathophysiological
mechanisms of the disorder are not well understood.
Research to date indicates that schizophrenia is a multi-
factorial neurodevelopmental impairment of the brain that
could be attributed to both genetic and environmental
factors [2, 7, 21, 23, 28]. Gene expression is readout of both
the genetic and the environmental factors that contribute
to the pathophysiology of schizophrenia. Analysis of
human postmortem brain is a powerful approach for the
identification of risk factors for schizophrenia, because
unlike studies of living patients, detailed molecular investi-
gations can be performed directly in the critical brain re-
gions of interest.
The pathophysiology of schizophrenia is likely to be
different between males and females. Sex differences
have been noted in several epidemiological analyses. For
example, several studies indicate that men have a slightly
higher incidence of schizophrenia compared with
women. In addition, males have an earlier age of onset
of schizophrenia, between 18–25 years of age, compared
with the female age of onset which is 25–35 years [20].
The symptoms exhibited by male and female patients
with schizophrenia also differ. Males tend to have a
greater vulnerability to negative symptoms and traits of
disorganization, while females more frequently exhibit
depressive symptoms [20]. These findings suggest that
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different underlying mechanisms of schizophrenia occur
in males and females. Therefore, we have investigated
sex differences in schizophrenia to gain a better un-
derstanding of the pathophysiological mechanisms
underpinning this disorder.
To identify the biological factors involved in the
pathogenesis of schizophrenia and how they are differen-
tially influenced in the sexes, we have investigated
microarray expression data from the prefrontal cortex
(PFC) in postmortem brain. The PFC region has been
strongly associated with deficits of executive function
and other cognitive symptoms that occur in patients
with schizophrenia. Gene expression within the PFC has
been studied extensively using the microarray approach
[4-6, 8, 9, 11, 13, 14, 16, 19, 24]. However, statistical ana-
lyses of gene expression data from individual small co-
horts have lacked sufficient statistical power to avoid
conflicting data in these different studies [17, 22]. Meta-
analysis is a strategy by which these problems could be
addressed, because the data from multiple studies can be
combined, thus increasing the statistical power available.
In this study, we have collected gene expression data
generated from post-mortem cohorts of schizophrenia
cases and psychiatrically healthy comparison groups that
are included in publicly available databases. We have
tested for sex differences in PFC gene expression in
schizophrenia, using the meta-analysis paradigm.
Methods and materials
Public microarray datasets of postmortem gene
expression in schizophrenia
We searched the public database and literature on the
study conducted on PFC region of postmortem brains and
decided to use Mistry’s merged expression dataset [17] for
further analysis because this combined cohort contains
the largest number of samples that could be accessed from
available resources. In Mistry’s study, the raw image data
of 306 postmortem brain samples from seven different
datasets were first pooled together, Robust Multi-array
Average (RMA) normalization procedure was then applied
on these pooled samples to obtain normalized expression
value of each probe set. Out of 306 samples, 246 are
available to the public. The RMA normalized expression
data (http://www.chibi.ubc.ca/wp-content/uploads/2013/
02/combined.data.txt) and corresponding clinical data
(http://www.chibi.ubc.ca/wp-content/uploads/2013/02/
combined.design.txt) of these 246 samples are available
for download on their website and will serve as a starting
point in this study. The source of six studies available to
the public in Mistry’s dataset is summarized in Table 1.
ComBat [12] batch effect adjustment was carried out in R
environment. We used ComBat() function included in the
“sva” package downloaded from BioConductor website
(https://www.bioconductor.org/packages/release/bioc/html/
sva.html) to perform batch effect correction on the original
dataset. Each study is treated as a batch and default param-
eter setup is used in running the ComBat function.
Differential expression analysis of each probe set
Expression values of each probe set were modeled using
a fixed effect linear model approach, where disease
status and imbalanced covariates between two groups
are treated as fixed effects to be estimated from data. A
model selection procedure was also employed for each
probe set to address the confounding effect of imbal-
anced covariates. The details of the procedure will be de-
scribed in next section. For each probe set, the t-statistic
for the disease effect was then extracted from the se-
lected model. P-values were computed using two-sided
t-test. The resulting P-values were further converted to
q-values using the qvalue package in R [25] which were
defined as the minimum positive False Discovery Rate
(q-value(t): Pr(H = 0|T > =t) in Bayesian interpretation
over a nested rejection region containing observed
statistics t) for multiple testing correction.
Covariate adjustment
The observed covariate imbalance between two groups
was analyzed to avoid generating misleading result.
However modelling covariates for every gene could
unnecessarily diminish statistical power if the covariate
does not influence the expression of the gene. In our
study, we consider only modelling imbalanced covariates
for each probe set. We first obtained a probe set (gene)
list where the covariate influence on the gene expression
is determined with confidence. This refined gene list was
generated using a previous method in a postmortem
brain gene expression study, in which a correlation
analysis was used to evaluate covariates such as age,
post-mortem interval, brain PH etc. that influenced the
expression of specific genes across multiple post-mortem
normal brain datasets [18]. We extracted genes with
meta-Q ≤ 0.01 to indicate that the gene was significantly
influenced by a particular covariate, and separate it into
two lists: positively-correlated and negatively-correlated.
Table 1 Public postmortem microarray datasets used in this study
Data set Brain region Control: Schizophrenia
Stanley Bahn [35] Frontal BA46 31(24M7F): 34(25M9F)






Mirnics [37] Prefrontal Cortex
(BA46)
6(4M2F): 9(5M4F)
Maycox GSE17612 [16] Anterior prefrontal
cortex (BA10)
21(12M9F): 26(18M8F)
Narayan GSE21138 [19] Frontal (BA46) 29(24M5F): 25(21M4F)
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Notice that one probe set could be mapped to multiple
genes, we excluded those probe sets appearing in the two
lists. For each predefined covariate influenced probe set,
we first modelled the expression value with a linear model
including that covariate. If the direction of the fitted co-
variate estimates was inconsistent with the pre-refined list,
we exclude this covariate and re-estimate a reduced model
for this probe set. For the rest of the probe sets, no covari-
ate adjustment was performed.
Selection of sex-specific differentially expressed genes
To identify genes that had a sex by diagnosis interaction
with schizophrenia, we used a strategy similar to [3]. Each
individual in our dataset is assigned to one of four sub-
groups: Schizophrenia Male, Control Male, Schizophrenia
Female and Control Female. Individuals could also be
combined into two groups based on their diagnosis:
Schizophrenia and Control group, or based on their sex:
Male and Female group. Differential expression analysis
was first performed using the procedure described in sec-
tion 2.2 within each sex. After the initial probe set list was
obtained from each sex, we further eliminated those probe
sets that are associated with schizophrenia regardless of
sex when all of the following criteria were met: (a) the
difference between Schizophrenia and Control groups
was statistically significant after multiple test correc-
tion (q-value < 0.05); (b) the fold change of Schizophrenia
Female vs. Control Females, and Schizophrenia Male vs
Control Males should be in the same direction i.e. both
higher or both lower; (c) the expression difference was not
significant between Male and Female groups (defined as
p > 0.05 between Female and Male group). After removal
of these probe sets from the initial probe set list, we sorted
the remaining probe sets within each sex by q-value and
report the top ranked probe sets (q-value < 0.05) as sex-
specific differentially expressed genes.
Function enrichment of differentially expressed genes
All differentially expressed genes, along with their Affyme-
trix ID numbers were imported into EASE (Expression
Analysis Systematic Explorer) in DAVID (Database for
Annotation, Visualization and Integrated Discovery), and
were used to identify functionally significant gene classes
(https://david.ncifcrf.gov/) [10]. This webserver uses statis-
tical methods to map and identify functional gene categor-
ies (for example, Gene Ontology (GO), Kyoto Encyclopedia
of Genes and Genomes (KEGG) or BioCarta), which are
enriched in the significant gene list compared with their
presence on the array.
Results
Batch and covariate adjustment
A total of 22277 probe sets is analyzed in this study.
Before further analysis, by using hierarchical clustering
analysis and Principal Component Analysis (PCA), we
found it was necessary to correct for “batch effect” as
samples from the same study were clustered together.
ComBat [12] was used to correct this technical bias by
treating each study as a batch. After ComBat adjust-
ment, the hierarchical clustering and PCA results show
that no significant clustering remained in the dataset
and the adjusted expression data was suitable for further
analysis (Additional file 1).
Clinical variables associated with each patient sample
were examined to determine possible confounding
variables. The age and postmortem interval (PMI) is well
matched between schizophrenia and control groups
while brain pH shows a significant difference between
two groups (Table 2). Within each sex group, we observe
that the brain PH is significantly different between
schizophrenia males and control males, on the other
hand, all covariates are well balanced in female group
(Table 2). Age at death was significantly different
between male and female group (Additional file 2). In
the predefined brain PH list, 2413 probe sets’ expres-
sions were positively correlated with the covariate and
893 were negatively correlated; in the predefined age
related list, the number is 1907 and 3028 respectively.
The imbalanced covariates and the proportion of probe
sets subject to covariate adjustment in each differential
analysis are summarized in Table 3.
Genes with altered PFC expression in schizophrenia
To validate our analytical approach used in this study, we
performed differential analysis between Schizophrenia and
Control group and compared the derived gene list with
two published results in which similar meta-analysis were
performed [17, 22]. We identified 466 probe sets (repre-
senting 427 unique genes) that were significantly down-
regulated in the schizophrenia cases relative to the
controls and 312 probe sets (representing 261 unique
genes) significantly up-regulated in schizophrenia with
q-value < 0.05. Our results show that a large number
of overlapped probe sets were observed between our
gene list and the other two studies (Fig. 1). All overlapped
probe sets showed the same direction of fold difference
between the schizophrenia cases and controls. In compari-
son with result of Mistry et al. [27], 86 out of 125 probe
sets (68.8 %) were also identified by our approach. In
comparison with result of Santiego et al., 98 out of
160 probe sets (61.3 %) overlapped with our result
[22]. Our method identified a similar proportion of
the probe sets from both studies.
We also examined whether the identified 778 probe sets
are associated with schizophrenia in case control studies
of genetic polymorphisms. We compared our gene list
with those deposited in SZGene (www.SZgene.org)
database which contains the most comprehensive review
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of schizophrenia association studies [31]. 80 probe sets
representing 68 unique genes are found to be genetically
associated with schizophrenia. Genes previously showing
strong genetic evidence implicated in schizophrenia
identified in this study include: regulator of G-protein
signaling 4 (RGS4) [32]; discoidin domain receptor family,
member 1(DDR1) [33]; and the selenium binding protein
1(SELENBP1) [34]. The full result is included in
Additional file 3.
Sex differences in PFC gene expression in schizophrenia
In the male group, we first identified 138 differentially
expressed probe sets with a q-value <0.05. We then re-
moved 80 probe sets which shows differential expression
regardless of sex based on the filter defined in the
Method part. 50 probe sets representing 46 unique genes
were identified as specifically different in male schizo-
phrenia patients relative to male controls: 23 probe sets
had lower expression (Table 4) and 27 probe sets have
higher expression (Table 5) in males with schizophrenia.
In the female group, we were not able to identify any
differentially expressed probe sets with q-value <0.05
after multiple testing correction.
Function annotation of male-specific differentially
expressed genes
The functions of 46 genes associated with schizophrenia in
male patients were manually inspected. Of the genes with
significantly lower expression in males with schizophrenia,
several were related to energy metabolism (ATP5B,
ATP5A1, MRPL23, AFG3L2, ABCG2). 4 genes (BEX1,
UBL4A, CD99 and MID1) located on the sex chromosome
are identified. We also detected differential expression of 4
genes in the males with schizophrenia that were previously
identified by Mistry et al. [17] in which sex was not consid-
ered. These were Rho-Related BTB Domain-Containing
Protein 3 (RHOBTB3), Bobby Sox homolog (BBX), H3
Histone, Family 3B (H3F3B) and pleckstrin homology
domain containing, family B (evectins) member 2
(PLEKHB2). Finally, using DAVID webserver, we per-
formed an enrichment analysis to systematically identify
over-representation of biological processes or pathways
that are altered in the PFC in male schizophrenia patients.
After correction for multiple comparisons, we were un-
able to identify any significant biological process (False
Discovery Rate <0.05) in the GO term Biological Process
database. We achieved similarly negative results using the
KEGG pathway database.
Discussion
We have reported the gene expression differences that
show a sex by diagnosis interaction in the PFC in schizo-
phrenia. To our knowledge, this is the first study using a
meta-analytical approach to identify sex differences in
this brain region in patients with schizophrenia. There
are limited data on sex differences in schizophrenia at a
molecular level [15, 29], although evidence from
epidemiological and animal studies indicates that sex
differences exist in this disorder [20, 27, 30]. Individual
post-mortem gene expression studies have low statistical
power to identify gene expression differences in schizo-
phrenia. This is, most often due to the small sample
sizes and moderate gene expression differences between
the diagnostic groups. Meta-analysis, on the other hand,
addresses this problem and increases statistical power by
combining samples from different subject cohorts. The
results obtained from our meta-analysis are robust at the
statistical level [17]. Our findings open a new window to
understand the different pathophysiological mechanisms
that lead to schizophrenia in males and females.
In the differential analyses between schizophrenia and
control group, we identified the most number of genes
most of which overlapped with the results of two
Table 2 Demographic data of postmortem subjects
Total sample Male group Female group
Control SCZ p-val Control SCZ p-val Control SCZ p-val
Size 124 122 89 90 35 32
Age 50.29 ± 17.2 51.09 ± 18.90 0.73 47.85 ± 16.44 48.45 ± 17.71 0.81 56.49 ± 17.89 58.53 ± 20.38 0.67
Gender 89 M:35 F 90 M:32 F >0.05 NA NA NA NA NA NA
Brain PH 6.48 ± 0.29 6.36 ± 0.29 0.002 6.50 ± 0.29 6.35 ± 0.26 <0.001 6.42 ± 0.29 6.40 ± 0.38 0.78
PMI3 25.49 ± 14.8 25.09 ± 15.9 0.84 26.12 ± 14.37 25.79 ± 16.45 0.89 23.91 ± 15.98 23.14 ± 14.34 0.84
Abbreviations: SCZ Schizophrenia, p-val p-value, M Male, F Female, PMI post-mortem interval
The summary demographics (mean ± s.d.) and t-test P-values for group difference are shown. For sex difference, we report the P-value generated from a
chi-square test for equality of proportions
Table 3 Covariate adjustment summary








Brain PH Brain PH Age
Proportion of probe
sets adjusteda (%)
11.87 % 11.47 % 18.00 %
aA total of 22777 probe sets is analyzed in this study
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previously published studies, while the other two pub-
lished studies had little overlap between each other
(Fig. 1). To find the reason for the difference, we run
the same procedure as in Mistry’s for our dataset. We
find that the main difference comes from different
treatment of “batch effect”. In Mistry’s study, they
treated each experiment date and study as batch vari-
able. A total of 50 batch date and 6 study was mod-
elled in their linear model framework. Introduction of
too many predictor variables will decrease the degrees
Fig. 1 Comparison of meta-analysis results among three studies
Table 4 Genes with altered expression in males with schizophrenia: downregulated probe sets
Probe set Gene symbol Locus Description Fold difference q-value
209735_at ABCG2 4q22 ATP-binding cassette, sub-family G (WHITE), member 2 −1.29 0.031
208868_s_at GABARAPL1 12p13.2 GABA(A) receptor-associated protein like 1 −1.17 0.043
208813_at GOT1 19q24.1-q25.1 glutamic-oxaloacetic transaminase 1, soluble
(aspartate aminotransferase 1)
−1.17 0.043
212878_s_at KLC1 14q32.3 kinesin light chain 1 −1.14 0.044
208002_s_at ACOT7 1p36 acyl-CoA thioesterase 7 −1.14 0.033
213897_s_at MRPL23 11p15.5 mitochondrial ribosomal protein L23 −1.10 0.043
211382_s_at TACC2 10q26 transforming, acidic coiled-coil containing protein 2 −1.10 0.033
214365_at TPM3 1q21.2 tropomyosin 3 −1.10 0.037
213738_s_at ATP5A1 18q21 ATP synthase, H+ transporting, mitochondrial F1 complex,
alpha subunit 1, cardiac muscle
−1.10 0.031
221909_at RNFT2 12q24.22 ring finger protein, transmembrane 2 −1.10 0.033
201322_at ATP5B 12q13.13 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide −1.10 0.049
203272_s_at TUSC2 3p21.3 tumor suppressor candidate 2 −1.09 0.049
218332_at BEX1 Xq22.1 brain expressed, X-linked 1 −1.09 0.033
201077_s_at NHP2L1 NA NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) −1.09 0.041
201410_at PLEKHB2 2q21.1 pleckstrin homology domain containing, family B (evectins) member 2 −1.08 0.033
219760_at LIN7B 19q13.3 lin-7 homolog B (C. elegans) −1.08 0.049
221315_s_at FGF22 19p13.3 fibroblast growth factor 22 −1.08 0.042
221706_s_at USE1 19p13.11 unconventional SNARE in the ER 1 homolog (S. cerevisiae) −1.07 0.042
202967_at GSTA4 6p12.1 glutathione S-transferase alpha 4 −1.07 0.049
207839_s_at TMEM8B 9p13.3 transmembrane protein 8B −1.07 0.042
221746_at UBL4A Xq28 ubiquitin-like 4A −1.07 0.033
208971_at UROD 1p34 uroporphyrinogen decarboxylase −1.07 0.043
202486_at AFG3L2 18p11 AFG3 ATPase family gene 3-like 2 (S. cerevisiae) −1.06 0.044
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of freedom of t-test on the estimated disease effect
coefficient, thus decreasing the likelihood of rejecting
the null hypothesis, leading to higher Type-II error.
Based on the observation of hierarchical clustering and
PCA result, we consider that modelling each study alone
would be sufficient to correct the batch effect. The second
reason explaining the difference is covariate adjustment.
We only include a covariate in the model when its influ-
ence on the gene is confirmed with confidence; while in
Mistry’s study, they assumed that the covariate influenced
every gene resulting in unnecessary inclusion of unrelated
variables in the model. Therefore the approach taken in
this study has more detection power and leads to discov-
ery of more genes.
Our analyses identified 46 genes that were differen-
tially expressed specifically in male patients with schizo-
phrenia. This finding of 50 probe sets is much larger
than the expected number of false positives according to
our selection procedure. The expected number of false
positives was calculated to be 6.9 (138*0.05 = 6.9). Five
genes were related to energy metabolism (ATP5B,
ATP5A1, MRPL23, AFG3L2, ABCG2). Genes from this
function category are consistently implicated in studies
of schizophrenia. Another gene that had altered expression
in the male schizophrenia group encodes γ-aminobutyric
acid receptor-associated protein-like 1 (GABARAPL1) is
an early estrogen-induced gene that when overexpressed,
interacts with GABA-A or κ-opioid receptors, and plays a
role in cell proliferation and cellular metabolic processes
[1]. Function enrichment analysis generates negative re-
sults for these genes, as indicated in other microarray
studies of the PFC in schizophrenia [17]. These results sug-
gest that a diverse number of molecular functions are dis-
rupted in males with schizophrenia.
No genes could be identified in female group after mul-
tiple testing correction (q-value < 0.05). To determine if
Table 5 Genes with altered expression in males with schizophrenia: upregulated probe sets
Probe set Gene symbol Locus Description Fold difference q-value
212226_s_at PPAP2B 1p32.2 phosphatidic acid phosphatase type 2B 1.32 0.043
202975_s_at RHOBTB3 5q15 Rho-related BTB domain containing 3 1.28 0.031
202935_s_at SOX9 17q24.3 SRY (sex determining region Y)-box 9 1.28 0.043
202887_s_at DDIT4 10q22.1 DNA-damage-inducible transcript 4 1.26 0.041
212859_x_at MT1E 16q13 metallothionein 1E 1.26 0.031
200897_s_at PALLD 4q32.3 palladin, cytoskeletal associated protein 1.24 0.031
200907_s_at PALLD 4q32.3 palladin, cytoskeletal associated protein 1.23 0.033
209210_s_at FERMT2 14q22.1 fermitin family member 2 1.22 0.033
213016_at BBX 3q13.1 bobby sox homolog (Drosophila) 1.21 0.031
213158_at unknown 3q13.2 unknown 1.21 0.042
201029_s_at CD99 Xp22.32/Yp11.3 CD99 molecule 1.18 0.043
218350_s_at GMNN 6p22.3 geminin, DNA replication inhibitor 1.17 0.033
214212_x_at FERMT2 14q22.1 fermitin family member 2 1.16 0.033
209069_s_at H3F3B NA H3 histone, family 3B (H3.3B) 1.16 0.037
205475_at SCRG1 4q34.1 stimulator of chondrogenesis 1 1.15 0.041
208022_s_at CDC14B 9q22.3 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 1.14 0.039
211997_x_at H3F3B NA H3 histone, family 3B (H3.3B) 1.14 0.038
41644_at SASH1 6q24.3 SAM and SH3 domain containing 1 1.13 0.044
215811_at Unknown gene NA - 1.13 0.047
209600_s_at ACOX1 17q25.1 acyl-CoA oxidase 1, palmitoyl 1.13 0.033
202771_at FAM38A 16q24.3 family with sequence similarity 38, member A 1.11 0.042
203636_at MID1 Xp22 midline 1 (Opitz/BBB syndrome) 1.11 0.049
200906_s_at PALLD 4q32.3 palladin, cytoskeletal associated protein 1.10 0.042
213342_at YAP1 11q13 Yes-associated protein 1 1.09 0.031
210105_s_at FYN 6q21 FYN oncogene related to SRC, FGR, YES 1.09 0.033
215823_x_at PABPC1 /// RLIM NA poly(A) binding protein, cytoplasmic 1 /// ring finger protein,
LIM domain interacting
1.08 0.044
210094_s_at PARD3 10p11.21 par-3 partitioning defective 3 homolog (C. elegans) 1.08 0.041
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this is due to a much smaller sample size than in male
group, we randomly picked the same number of control
and schizophrenia subjects from the male groups ten
times and run differential analysis on these samples. The
procedure was repeated 100 times. No significant differ-
ence could be detected in the expression level of any gene
in the phenotype groups (data not shown). We then
gradually increase the number of samples until genes
could be detected with q-value < 0.05 in each run. We
started to identify differentially expressed genes when
there are 60 controls and 60 schizophrenia in the sample
pool. This analysis showed that increasing the number of
samples would improve the likelihood of identifying
schizophrenia-associated genes in the females.
Very few studies have been conducted of sex
differences in gene expression in the PFC in schizophre-
nia. Vawter et.al. [29] reported that three genes (MDH1,
HINT1 and SERPINI1) had decreased expression in PFC
region of 13 male schizophrenia patients compared with
11 male controls and no expression difference was
observed in comparing 9 female schizophrenia patients
with 10 female controls using quantitative PCR. We then
extracted the corresponding probe sets from our dataset
and summarized the result in Table 6. We observed
significantly lower expression levels of all three genes in
the schizophrenia group compared with controls
(Table 6, Column 3 and 4). The expression difference of
these 3 genes in was also tested in males and females
separately (Table 6, Column 5 to 8). Our analysis sug-
gests that all three genes might be altered by schizophre-
nia and are not related to sex difference. For MDH1, the
expression is significantly decreased in the schizophrenia
group of both sexes suggesting that this gene might be
down-regulated in schizophrenia regardless of sex. HINT1
and SERPINI1 do not show differential expression
between the male and female groups (Table 6, Column 9).
Our study has a larger sample size than that of Vawter et
al. thus we have greater statistical power to detect small
effects, and we would argue that these genes are associ-
ated with schizophrenia but are not differentially
expressed between the sexes.
Conclusion
In summary, this is the most comprehensive and up-to-
date analysis of sex differences in prefrontal cortex gene
expression in schizophrenia. Some of our data con-
solidate the reports of previously published papers.
Our results indicate that further investigation of sex
differences in schizophrenia is required [15]. These
data bring us closer to understanding the different
molecular mechanisms underpinning schizophrenia in
males and females, so that novel targets for antipsychotic
drug development can be identified. Genes with altered
expression in schizophrenia can also serve as biological
markers for the disorder, so that biochemical diagnostic
tools can facilitate the practice of clinical psychiatry.
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